DexTech Medical will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 SEK | -1.36% | -12.85% | +10.43% |
04-26 | Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
04-15 | DexTech Medical Announces New Positive Results from the Myeloma Study | CI |
1st Jan change | Capi. | |
---|---|---|
+10.43% | 7.5M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.64% | 22.28B | |
-11.90% | 22.41B | |
-5.57% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- DEX Stock
- News Dextech Medical AB
- DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex